03 August 2021
The ongoing controversy over Biogen's Aduhelm treatment shows that pricing scrutiny has risen to a new level. Pharmaceutical experts warn that...
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Life Sciences Research and Analysis
Find timely insights, commentary and special reports from industry leading experts and analysts.
Industry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence.
Featured
Browse Content
-
-
27 July 2021 Margaret Labban, Ph.D. Lindsay Newman, Ph.D.
COVID-19 vaccine likely to drive lasting change in vaccine trade as vaccines become key factor in global diplomacy
-
20 July 2021 Brendan Melck
New ESG requirements in the LkSG act will impact pharmaceutical supply chains. Our analyst takes a close look at how this can change drug pricing...
-
07 July 2021 Margaret Labban, Ph.D. Floriane Reinaud
A look at what the delay in Canada's new PMPRB reforms means for the industry
-
29 June 2021 Eoin Ryan
Concessions and opt-outs offered to national HTA authorities amount to a “missed opportunity” and an efficient one-stop-shop for joint clinical...
-
24 June 2021 Sophie Cairns Margaret Labban, Ph.D.
Delytact is not the first oncolytic virus to garner marketing approval globally, however the latest development could signal the resurgence of...
-
16 June 2021 Milena Izmirlieva
Combination therapies in breast cancer face greater challenges in cost-effectiveness assessments compared to monotherapies, as demonstrated by...
-
09 June 2021 Margaret Labban, Ph.D. Janet Beal Floriane Reinaud
Northern Ireland could end up paying higher costs for certain generic products if indeed it must source drugs from the Republic of Ireland due...
-
Pharmaceutical crisis deepens in Lebanon as central bank unable to meet cost of subsidized medicines
04 June 2021 Sacha Baggili
Pharmaceutical crisis deepens in Lebanon as central bank unable to meet cost of subsidized medicines
-
25 May 2021 Janet Beal
Use of the Project Orbis joint review scheme has enabled UK approval of Tagrisso for a key cancer indication ahead of the EU.
-
18 May 2021 Will Iacobucci Kari Jones, Ph.D.
Despite the arguments for or against mandated minimum staffing ratios in hospitals, currently an insufficient number of nurses practice in New...
-
13 May 2021 Margaret Labban, Ph.D. Floriane Reinaud
Understanding drug pricing structures in CEE countries
-
06 May 2021 Lindsay Newman, Ph.D. Janet Beal Eoin Ryan
Although largely symbolic, the move could set a precedent for governments exerting pressure on pharma companies to release IP
-
05 May 2021 Gustav Ando Floriane Reinaud
We use our inhouse data and visualization tool to understand the reasons behind medicines price changes.
-
28 April 2021 Margaret Labban, Ph.D.
The potential cost to global trade from accelerated efforts to onshore production of essential products may be gravely underestimated.
-
22 April 2021 Sophie Cairns
Japan sets a significant milestone of applying cost-effectiveness to reimbursement price assessments, indicating growing pricing pressure for...
-
16 April 2021 Milena Izmirlieva
Vaccine hesitancy – driven by safety concerns for adenovirus-based COVID-19 vaccines – is delaying vaccine delivery in some countries and is...
-
14 April 2021 Milena Izmirlieva Lindsay Newman, Ph.D. Gustav Ando Dijedon Imeri
Vaccine nationalism represents significant risk to prolonging the COVID-19 pandemic well into 2022 and 2023
-
31 March 2021 Eoin Ryan
Biomarker testing in Europe looks potentially very promising, and provided challenges to the market access space are overcome, there could be...
-
25 March 2021 Margaret Labban, Ph.D.
Biden's first P&R policy could cut pharmaceutical spending by USD16 billion over 10 years
-
18 March 2021 Floriane Reinaud
We look at the impact of AMNOG on drug price, access, and launch sequences a decade later
-
10 March 2021 Ewa Oliveira da Silva Brendan Melck Anne Charlotte Ackermann, M.A
As drug shortages significantly worsened during 2020, pharmacists in four European countries have trialed a collaborative solution to improve...
-
03 March 2021 Milena Izmirlieva Floriane Reinaud Anne Charlotte Ackermann, M.A
A close examination of vaccine APAs and pricing estimates as vaccination campaigns continue to roll out globally.
-
23 February 2021 Sacha Baggili
With new Ebola Cases reported in Guinea and the Democratic Republic of Congo, we look at the heightened risks involved and the new tools at hand...
-
18 February 2021 Sophie Cairns Anne Charlotte Ackermann, M.A
As China starts the Year of the Ox, we take a look at what to expect from the world’s second-largest pharmaceutical market including a burgeoning...
-
10 February 2021 Niklas Wallin Bernhardsson Milena Izmirlieva Anne Charlotte Ackermann, M.A
In our Q1 2021 forecast round, we raised our global healthcare spending forecast for 2021, as the resurgence in COVID-19 infections triggered...
-
08 February 2021 Margaret Labban, Ph.D. Floriane Reinaud
Slight rebound in US drug price increases signal new era, although one likely fraught with new challenges for the industry
-
27 January 2021 Milena Izmirlieva Anne Charlotte Ackermann, M.A
For the healthcare sector, 2021 will be a year of constant adjustment, with many implications in terms of strategic planning, market access...
-
21 January 2021 Eoin Ryan
Daily administration rates of COVID-19 vaccines in EU countries show that countries that have languished near the bottom of the vaccination league...
-
11 January 2021 Janet Beal Gustav Ando
Our life sciences team looks at new strains of the virus and the massive vaccination campaigns unfolding around the globe
-
09 December 2020 Eoin Ryan Choukri Genane
Our ProcureIntel analysis highlights growing space for the inclusion of ESG criteria in the top-5 European markets between 2014 and 2020.
-
01 December 2020 Sophie Cairns Cameron Lockwood
China’s massive investment in innovative pharma has the potential to be a gamechanger for multinationals operating in the domestic market.
-
12 November 2020 Margaret Labban, Ph.D.
Pfizer and BioNTech's COVID-19 vaccine demonstrates over 90% efficacy as hope builds for an early end to the pandemic Pfizer (US) and partner...
-
26 October 2020 Gustav Ando
We are expecting major clinical readouts from several key COVID-19 vaccine and therapeutics candidates- our weekly R&D Tracker gives us insights....
-
20 October 2020 Sophie Cairns
Amid global COVID-19 chaos, Japan quietly fosters innovation in its regenerative sector
-
18 September 2020 Margaret Labban, Ph.D. Floriane Reinaud Cameron Lockwood
President Trump's most-favored-nation order could cut high-cost drug prices by over 80%
-
01 September 2020 Milena Izmirlieva Jing Zhang
With a spend of USD 8.3 trillion this year and 8.8 trillion in 2021 economic contractions will be offset by increased government healthcare funding...
-
03 August 2020 Margaret Labban, Ph.D.
The advance purchase agreement from the US government for BNT 162 provides the first pricing benchmark of around USD20 per dose for a COVID-19...
-
29 July 2020 Kari Jones, Ph.D.
While much of the commentary about whether and how to re-open schools is political and simplistic, the issue is quite complex, and further complicated...
-
27 July 2020 Milena Izmirlieva
Monitoring of pharmaceutical prices in other countries will become a major part of US government policy and its negotiating strategy going forward...
-
21 July 2020
Older adults in the U.S. are at higher risk for cardiovascular-related mortality associated with climate change.
-
08 July 2020 Gustav Ando
Smaller markets hit particularly hard by supply chain disruption
-
07 July 2020 Milena Izmirlieva Margaret Labban, Ph.D.
Despite the call for solidarity, some countries are likely to continue to engage in more explicit acts of vaccine nationalism, driven by domestic...
-
29 June 2020 Margaret Labban, Ph.D.
Recovering R&D costs in 2020 would be crucial to mitigating long-term risks
-
11 June 2020 Janet Beal Gustav Ando
Generating an effective vaccine with any long-term effect has initiated a diverse selection of vaccine projects- what does it really look like?...
-
29 April 2020 Margaret Labban, Ph.D.
While the Oxford group's vaccine appears to be one of the leading candidates currently in development, several factors could affect the candidate’s...
-
24 April 2020 Sacha Baggili, B.A, M.A Margaret Labban, Ph.D.
US guidelines for opening up again converge with WHO guidelines, but set a lower bar for starting relaxations
-
21 April 2020 Mr. Eoin Ryan
Could national healthcare emergencies delay price framework agreements in parts of Europe?
-
30 March 2020 Gustav Ando
Resource issues underscore the importance of international trade for medical supplies
-
20 March 2020 Tim Dall
Health workers on front lines treating people with COVID-19 are at high risk -- what changes are needed?
-
19 March 2020 Milena Izmirlieva
Countries have inadequate health system surge capacity to deal with COVID-19 pandemic
-
26 February 2020 Janet Beal
As the UK government steps up its preparedness plan for any national spread of the COVID-19 outbreak, it has suspended parallel export for two...
-
27 December 2019 Sophie Cairns
China’s young biosimilars market is taking off, with a raft of approvals of domestically-developed biosimilars expected in the next few years....
-
18 December 2019 Brendan Melck
New originator biologics are being added to the reimbursement list in Poland, but they are simply not reaching a sufficient number of patients....
-
11 December 2019 Tania Rodrigues
Discussions around collaboration and precision medicines from ISPOR Europe
-
02 December 2019 Milena Izmirlieva
Danger for UK healthcare spending may not be from rising drugs prices or from reducing the ability of the NHS to negotiate drug prices but from...
-
04 November 2019 Milena Izmirlieva
Insights from ISPOR 2019: Challenges that payers in Central and Eastern European (CEE) countries face when trying to devise risk sharing agreement...
-
04 November 2019 Brendan Melck
Germany’s health minister Jen Spahn is seeking to resolve a long-running dispute with the European Commission over fixed drug pricing rules
-
30 October 2019 Tania Rodrigues
Slovakia approved legislation to curtail alleged manufacturer attempts to circumvent IRP-related price reductions by marketing unique presentations...
-
02 October 2019 Frank Chen
Expanding Medicare coverage to both lifestyle interventions and medication could lead to long-term reductions in health care spending.
-
01 October 2019 Sophie Cairns
South Korean drug makers have seen several high-profile setbacks in recent months. What does this mean for overseas pharma?
-
26 September 2019 Will Iacobucci Timothy Dall
The total economic burden associated with elevated blood glucose levels in the United States reached nearly $404 billion in 2017
-
12 August 2019 Cameron Lockwood
Alive and kicking, this policy tool continues to feature prominently in the pricing framework of many markets, mature and emerging alike.
-
02 August 2019 Eoin Ryan
Ireland's high level of pharma waste exports - rather than dealing with the problem at source - prompts Takeda's call for infrastructure investment...
-
19 June 2019 Margaret Labban
Following the developments of Pharmacare in Canada as it breaks new ground with a universal, publicly-funded drug plan
-
17 June 2019 Sophie Cairns
Despite China’s efforts to rein in drug prices, pockets of high prices persist.
-
30 May 2019 Ewa Oliveira da Silva
Argentina's recent reimbursement deal with Biogen is of note for manufacturers of other high-cost therapies
-
17 May 2019 Margaret Labban
Spend 2 minutes with our analyst, Margaret Labban, on Pharmacare
-
17 May 2019 Brendan Melck
Bulgaria's new P&R policies are a double blow to the pharma industry
-
03 May 2019 Janet Beal
As a new one-off gene therapy for SMA nears the US market, effective pricing will be crucial in ensuring sustainable patient access.
-
17 April 2019 Sacha Baggili
India's new clinical trial rules establish an accelerated pathway for new drug approvals, but affordability remains a barrier to access.
-
12 April 2019 Milena Izmirlieva
Democrats explore creative ways to expand health insurance access with Medicare X
-
02 April 2019 Margaret Labban
The creation of the Canadian Drug Agency and Pharmacare could mean big changes for drug prices
-
29 March 2019 Eoin Ryan
Norway’s Statistik Sentralbyrå (SSB) annual healthcare and pharmaceutical expenditure statistics confirms the accuracy of IHS Markit’s healthcare...
-
12 March 2019
Using our model we examine the budget impact of passing through a share of negotiated manufacturer rebates to patients at POS
-
12 February 2019 Milena Izmirlieva
Our latest quarterly forecast, released in January 2019, indicates that public spending in the United States will account for more than 86% of...
-
28 December 2018 Cameron Lockwood
Significant discrepancies remain between the access conditions of different countries
-
13 December 2018 Frank Chen
Using a published and validated microsimulation model, we predicted the annual number of overdose, mortality, and direct medical costs associated...
-
28 November 2018 Praful Mehta Eoin Ryan
Tenders for biosimilars for Humira in both Denmark and Italy mark a dramatic shift
-
14 November 2018 Cameron Lockwood
International reference pricing of pharmaceuticals: Apply liberally or use sparingly?
-
14 November 2018 Milena Izmirlieva
The impact of expedited marketing authorisation on P&R outcomes for drugs in the US and EU-5
-
12 November 2018 Gustav Ando
Meet us at ISPOR, come see our posters, chat with us about our new product innovations
-
08 November 2018 Gustav Ando
US gets the headlines, but Greece and Denmark have more immediate impact
-
06 November 2018 Ewa Oliveira da Silva
Inefficiency in the centralized model behind Mexico's tendering decline
-
17 October 2018 Brendan Melck
Discounts provided to Czech state hospitals in tenders showed that manufacturers are offering discounts on that reduce the ultimate price to...
-
08 October 2018 Eoin Ryan
The co-ruling Five Star Movement (Movimento Cinque Stelle: M5S) has voiced criticism of the economic case for pharmaceutical tenders in Italy...
-
05 October 2018 Eoin Ryan
To curb shortages, Norway's pharma industry turns to a number of mechanisms to ensure that the country maintains low drug prices in relation...
-
28 September 2018 Eoin Ryan
If UK and EU negotiators are unable to conclude a withdrawal and transition agreement, the likelihood of UK participation in the UPC and unitary...
-
27 September 2018 Sophie Cairns
Asia’s emerging pharmaceutical markets are likely to focus increasingly on Health Technology Assessment as healthcare costs rise.
-
20 September 2018 Sophie Cairns
Insights from The Pharma Market Access and Pricing Summit Asia
-
16 August 2018 Ewa Oliveira da Silva
Policy uncertainty is set to remain high as the government may struggle to pass major reforms
-
10 July 2018 Sophie Cairns
Takeda’s proposed purchase of Shire has led to shareholder dissent; however, M&A is expected to continu
-
22 May 2018 Gustav Ando
Insights from ISPOR Baltimore 2018 - digital health
-
18 May 2018 Gustav Ando
Meet us at ISPOR, come see our posters, chat with us about our new product innovations
-
17 May 2018 Brendan Melck
Will shortages lead to changes in the discount-contract system?
-
11 May 2018
Passing through a portion of rebates could generate substantial savings across the entire Medicare program
-
19 April 2018 Sophie Cairns
Proposed tariffs on Chinese-made goods, including pharmaceutical ingredients, are expected to affect mainly US generics makers.
-
27 March 2018 Ritashree Chakrabarti Tim Dall
Updates to the previous estimates on the burden of disease
-
26 March 2018 Tania Rodrigues
Colombia embraces value-based pricing with Decree 433 of 2018 for new innovative drugs at market entry
-
14 March 2018 Ewa Oliveira da Silva
Is risk-sharing the way forward for this cash-strapped public healthcare system?
-
28 February 2018 Eoin Ryan
Reforms face a difficult path to implementation and the real possibility that they may require careful modification.
-
07 December 2017
Over the next 10 years, Medicare is expected to save $19 billion
-
04 December 2017 Milena Izmirlieva
Consumer access to effective and affordable medicines in the US is currently inadequately served by the pharmaceutical sector
-
28 November 2017 Eoin Ryan
Luring the EMA to Amsterdam marks a stunning diplomatic coup
-
14 November 2017 Ewa Oliveira da Silva
After October election strengthens government will public healthcare reform see a change?
-
13 November 2017 Anne-Charlotte Ackermann
A value-based approach or a cost-effectiveness or efficacy approach?
-
09 November 2017 Frank Chen
State-by-state projected annual savings to Medicaid from better management of diabetes
-
03 November 2017 Janet Beal
The UK government has issued its much-anticipated response to the Accelerated Access Review (AAR)
-
01 November 2017 Gustav Ando
Meet with our experts and analysts in Glasgow next week
-
23 October 2017 Sophie Cairns
China removes the requirement for local clinical data as part of the drug approval process
-
18 October 2017 Janet Beal
UK access to medicines during and after Brexit
-
16 October 2017
A close look at pharma strategy in the Middle East
-
28 September 2017 Tania Rodrigues
A look at how the formal use of IRP is evolving in Brazil compared to Colombia.
-
12 September 2017 Brendan Melck
How does Lithuania plan to reducethe cost of medicines?
-
29 August 2017 Ewa Oliveira da Silva
Where will the EMA locate after Brexit? Can Spain be the answer?
-
17 August 2017 Cameron Lockwood
Is IRP a self sustaining dynamo or soon to be eclipsed?
-
04 August 2017 Sophie Cairns
China adds another 36 medicines to NRDL
-
28 July 2017 Milena Izmirlieva
What was the "Skinny Bill" and what's next?
-
18 July 2017 Cameron Lockwood
At what point will payers decide that opacity in the prices being referenced renders the tool meaningless?
-
11 July 2017
Drug shortages and the insufficient control systems in many Middle East countries have also allowed illegal mega-manufacturing factories to work...
-
16 June 2017 Praful Mehta
IHS Markit and Context Matters have for the first time combined these two diverse datasets under one platform so that companies can draw meaningful...
-
08 June 2017 Sophie Cairns
There is increasing public debate over whether Hong Kong's cash-rich government should give more public funding to rare rare-disease medicines....
-
31 May 2017 Milena Izmirlieva
How oil prices undermine a country's ability to pay for medicines
-
24 May 2017 Margaret Labban
A deeper look at US healthcare reform
-
23 May 2017 Gustav Ando
Insights from Day one at ISPOR Boston: US healthcare reform
-
22 May 2017 Gustav Ando
IHS Markit's life sciences team is at ISPOR this week.
-
10 May 2017 Janet Beal
Ukraine has remained the only European country where until very recently patients have largely had to pay out-of-pocket
-
03 May 2017 Brendan Melck
Tensions between the pharmaceutical industry and the social security institutions in Austria are high again
-
13 April 2017 Eoin Ryan
The latest analysis could facilitate future cross-border procurement structures between two or more Nordic countries
-
27 March 2017 Tania Rodrigues
best IRP practice considerations from an industry standpoint
-
21 March 2017 Milena Izmirlieva
A look at some of the developments in cross-country procurement and its possible negative impact for Industry
-
17 March 2017 Praful Mehta
There are clear signals in the EU that the market access environment will become more stringent in the coming years
-
10 March 2017 Cameron Lockwood
A look at SB-17 and what it means for drug pricing in CA
-
06 March 2017 Margaret Labban
The five key principles that need to be present in new legislation that would replace the ACA
-
24 January 2017 Gustav Ando
The Patient Reported Indicators Survey (PaRIS) was formally launched with the ambition of becoming the pre-eminent standard to measure quality...
-
05 January 2017 Tania Rodrigues
A survey of heads of HTA agencies in middle-income countries in Central and Eastern Europe (CEE), Latin America and Asia showed reservations...
-
28 December 2016 Tania Rodrigues
Whilst at ISPOR Vienna, I attended a lively session on national health economic guidelines in Southern Europe that highlighted how current practice...
-
18 November 2016 Janet Beal
A deeper look at the UK's Accelerated Access Review
-
14 November 2016 Cameron Lockwood
An independent assessment of what the pharmaceutical industry is doing to help make medicines more accessible in low- and middle-income countries...
-
11 November 2016 Milena Izmirlieva
Early expectations for the pharmaceutical industry as a result of the Trump election.
-
08 November 2016 Gustav Ando
Proposition 61 on today's California ballot
-
01 November 2016 Gustav Ando
Insights from 19th annual European Congress of ISPORin Vienna
-
28 October 2016 Tania Rodrigues
President Mauricio Macri's bill for the creation of a formal HTA agency
-
26 October 2016 Tania Rodrigues
Education on rising drug costs
-
14 September 2016 Sophie Cairns
Japan's Ministry of Foreign Affairs issued an unusually direct warning of "great turmoil" in a post-Brexit scenario
-
09 September 2016 Eoin Ryan
Ireland's IRP framework underwent a major shake-up in August including an expansion of the basket
-
06 September 2016 Brendan Melck
industry fears hit from reimbursement restrictions
-
02 September 2016 IHS Markit Life Sciences Expert
The new insurance scheme may have negative effects for critically ill-patient groups.
-
19 August 2016 Angelica Kershaw
Public health experts have welcomed the new approach of some pharmaceutical companies towards unveiling new patent policies facilitating access...
-
15 August 2016 Cameron Lockwood
The field of advanced molecular diagnostics, including next-generation sequencing (NGS), has had a complicated history in Germany. When we performed...
-
01 August 2016 Sophie Cairns
A win that is bittersweet
-
28 July 2016 IHS Markit Life Sciences Expert
The people of Syria are now facing the spread of the serious but non-lethal skin infection
-
19 July 2016 Milena Izmirlieva
Pinpointing the exact impact of Brexit on healthcare spending and pharmaceutical spending remains a moving target
-
18 July 2016 Tania Rodrigues
The Spanish health sector is awaiting the formation of a coalition government that will help navigate a complex multi-party regional political...
-
11 July 2016 Eoin Ryan
Major economic and political uncertainty across both UK and EU markets is likely to hamper the EMAs relocation and complicate the decision
-
08 July 2016 Jing Zhang
What is the economic health of South America for pharma?
-
06 July 2016 Cecilia Chui
Immunotherapy and precision medicine centre-stage at ASCO
-
30 June 2016 Cameron Lockwood
Question marks over the sustainability of industry pipelines have been replaced by question marks over the sustainability of healthcare systems...
-
27 June 2016 Angelica Kershaw
Resolution 2475/2016 authorises the Inter-ministerial Medicines and Medical Devices Pricing Commission (CNPMD) to reduce Glivec's price.
-
A vote to leave the European Union and what it would mean for Britain's place in the world of pharma
20 June 2016 Milena Izmirlieva
As the date for Great Britain's referendum on whether to leave the European Union approaches, the pre-referendum debates have only marginally...
-
17 June 2016 Anne-Charlotte Ackermann
A close look at France's formal BIA and access to HCV meds
-
14 June 2016 Janet Beal
A cheaper, faster track to approve funding for me-too medicines in the UK?
-
10 June 2016 Brendan Melck
A familiar problem in Greece today: trying to implement reforms which are difficult enough to implement in normal circumstances...
-
01 June 2016 Sophie Cairns
Pricing and cost-effectiveness and public hospital discussions from our trip to Asia
-
26 May 2016 Cameron Lockwood
A look at some of the challenges facing the NHS commissioning framework for molecular diagnostic testing
-
23 May 2016 Cameron Lockwood
AA closer look at the access-to-medicines debate
-
18 May 2016 Cameron Lockwood
A new and easy way to access our multi client studies
-
21 April 2016 Angelica Kershaw
The latest on the spread of Zika and developments to address the current outbreak
-
22 March 2016 Tania Rodrigues
A close look at the recent developments with DRGs
-
06 March 2016 Cameron Lockwood
In late February, the Obama administration announced a number of actions designed to accelerate the development of precision medicine in the...
-
29 February 2016 Eoin Ryan
The new EFPIA code introduces a significant new level of public scrutiny
-
02 February 2016 Choukri Genane
A close look at the proposed appointment of haematology specialist Buzyn Agnes
-
10 January 2016 Cecilia Chui
A closer look at precision Meds
-
03 January 2016 Zhang, Jing
Understanding Chinese traditional medicine
-
27 December 2015 Zhang, Jing
Understanding the twentieth-largest pharmaceutical market in the world
-
21 December 2015 Brendan Melck
How over the counter meds are changing the market landscape
-
10 December 2015 Milena Izmirlieva
A look at the pricing for PCSK9 inhibitors for cholesterol
-
07 December 2015 Floriane Reinaud
Options when the price requested by the pharmaceutical company is believed to be too high
-
02 December 2015 Sophie Cairns
Vietnam's pharmaceutical sector is expected to see the fiercest competition
-
30 November 2015 Maria McGee
Time and again when we explore ways in which we can streamline market access, secure reimbursement and even refine pharmaceutical pricing, we...
-
23 November 2015 Gustav Ando
Insights on the Pfizer/ Allergan merger
-
19 November 2015 Brendan Melck
What are the implications for healthcare following the elections?
-
17 November 2015 Milena Izmirlieva
Insights from ISPOR Milan - parallel scientific advice by regulatory agencies and HTA agencies
-
15 November 2015 Gustav Ando
A healthcare system in crisis, a pharmaceutical industry in decline, and acute shortages of essential medicines
-
13 November 2015 Milena Izmirlieva
Insights from ISPOR Milan 2015 on managed entry agreements
-
10 November 2015 Tania Rodrigues
Discounts usually offered to distributors and retailers will be slashed
-
09 November 2015 Gustav Ando
Insights from ISPOR Milan
-
08 November 2015 Kavita Rainova
Is England's Cancer Drug Fund sustainable?
-
04 November 2015 Cameron Lockwood
The value of molecular testing will increasingly hinge on experimental demonstration of clinical utility
-
03 November 2015 Eoin Ryan
Ongoing price reductions negotiations covering the supply of innovative medicines
-
30 October 2015 Gustav Ando
Booth 1015 and during session 3 of research posters
-
26 October 2015 Angelica Kershaw
Insights from ISPOR Latin America on HTA and centralized procurement
-
20 October 2015 Sophie Cairns
In Hong Kong's flourishing black market, costly branded drugs can be bought at a fraction of their market price
-
13 October 2015 Maria McGee
A close look at AstraZeneca´s most recent biomarker technology collaboration
-
09 October 2015 Choukri Genane
A look at the ongoing struggle for the French government with its health deficit
-
05 October 2015 Tania Rodrigues
The state of precision medicine in Spain
-
14 September 2015 Kavita Rainova
The vaccines situation raises concerns over the potential rise in other vaccine-preventable diseases
-
09 September 2015 Mark Hollis
Governments in the region are increasingly working together to harmonize regulatory approvals
-
03 September 2015 Floriane Reinaud
Can European governments fund new and innovative pharmaceuticals given their growing debt?
-
27 August 2015 Eoin Ryan
Diabetes-related social and economic costs amounted to DKK31.8 billion (USD4.75 billion) in 2011, corresponding to DKK107,000 (USD16,000) per...
-
25 August 2015 Cameron Lockwood
A close look at the market-specific differences in terms of how payers would like to see manufacturers address the REA gap
-
19 August 2015 Sophie Cairns
IHS Life Sciences expects the explosion to cause significant disruption to the shipment of non-time-sensitive pharmaceutical exports
-
17 August 2015 Cecilia Chui
What gets covered when a patient receives both insured and uninsured treatments in the same medical care series?
-
31 July 2015 Cameron Lockwood
Understanding what's at stake, and behind, the changes within the Saudi MOH
-
28 July 2015 Tania Rodrigues
The quest to dramatically change the molecular diagnostic landscape and ultimately provide a global vision of cancer treatment in Spain.
-
23 July 2015 Angelica Kershaw
According to the MoH, with the implementation of these partnerships the Brazilian government has achieved BRL2.5 billion (USD782.2 million) in...
-
21 July 2015 Mark Hollis
Does the UNAIDS report whitewash over the very real funding crisis facing HIV treatment programs?
-
16 July 2015 Kavita Rainova
Do these new documents point to a single drugs market within the Eurasian Economic Union (EEU)?
-
14 July 2015
Using our disease prevention microsimulation model to understand the true burden of disease
-
08 July 2015 Sophie Cairns
Thailand's battle against runaway pharmaceutical prices.
-
06 July 2015 Zhang, Jing
A closer look at South Korea's healthcare economy
-
30 June 2015 Milena Izmirlieva
Are there signs of actual changes in the United States P&R environment as a result of the 'Sovaldi Effect'?
-
26 June 2015 Margaret Labban
A global perspective on Gilead's pricing strategy. The Sovaldi debate continues
-
22 June 2015 Kavita Rainova
A closer look at the Ukrainian healthcare system amidst the country's ongoing turmoil
-
17 June 2015 Maria McGee
Sweden looks to reform its pricing model.
-
14 June 2015 Tania Rodrigues
Is global action needed to curb wide-spread use of antibiotics and the development of drug-resistant bacteria?
-
05 June 2015 Cecilia Chui
Tracking shifts in MENA healthcare systems
-
02 June 2015 Cameron Lockwood
The Middle East and North Africa is a region once again on the radar, following recent rumours that Valeant is considering a bid for Egypt's...
-
27 May 2015 Angelica Kershaw
A close look at the drug shortages in Venezuela
-
19 May 2015 Gustav Ando
Insights on regulations from #ISPORPhila
-
18 May 2015 Gustav Ando
insights from #ISPORPhila 2015
-
14 May 2015 Brendan Melck
Insights from the European Generics Association's (EGA) annual biosimilars conference.
-
12 May 2015 Margaret Labban
On average, an estimated CAD7.3 billion (USD5.95 billion) in savings could be achieved in Canada through a universal drug plan.
-
07 May 2015 Gustav Ando
IHS Life Sciences will be at ISPOR May 16-20
-
05 May 2015 Mark Hollis
A look at the changing healthcare policy in India. Is it the end of the move towards universal coverage?
-
29 April 2015 Cameron Lockwood
A look at the "barriers to access" for Sovaldi
-
26 April 2015 Floriane Reinaud
IHS Life Sciences analysed price changes for innovative drugs approved by the European Medicines Agency (EMA) that were priced in 2009 and afterwards....
-
24 April 2015 Mark Hollis
In the lead-up to World Malaria Day, the World Health Organization has published new guidelines on the clinical management of malaria. In addition...
-
23 April 2015 Sophie Cairns
A look at China's CFDA new regulations on far-flung corners of its pharmaceutical sector: multi-regional clinical trials, biosimilars, drug evaluation...
-
21 April 2015
The importance of Health Impact Assessments (HIA) as a means of adding unique insights to a one dimensional analysis
-
15 April 2015 Praful Mehta
A look at M&A activity for the industry
-
13 April 2015 Angelica Kershaw
A deeper look at Colombia's "healthcare statutory law
-
09 April 2015 Brendan Melck
Poland's pharmaceutical industry has reacted with strong condemnation to a letter sent by the deputy health minister to the country's health...
-
06 April 2015 Federica Benassi
Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) are expected to become the next cardiovascular blockbusters able to...
-
02 April 2015 Maria McGee
The Swedish government has announced it is drawing on Danish experiences to improve cancer care by introducing standardised cancer care pathways...
-
31 March 2015 Margaret Labban
The pricing and reimbursement (P&R) landscape for pharmaceuticals is gradually changing in Canada, particularly as the provinces have banded...
-
25 March 2015 Anne-Charlotte Ackermann
We examine how the new pharmaco-economic evaluations impact market access conditions for innovative medicines in France.
-
23 March 2015 Zhang, Jing
A close look at the the outlook for the Philippines and the pros and cons of joining the Trans-Pacific Partnership (TPP)
-
16 March 2015 Kavita Rainova
As of 12 March, some of the drugs that were previously funded through the Cancer Drug's Fund (UK) have been de-listed.
-
06 March 2015 Will Iacobucci
The Association of American Medical Colleges (AAMC), an organization that represents the accredited medical schools and teaching hospitals in...
-
03 March 2015 Milena Izmirlieva
Learn more about the trends in risk sharing agreements (known as patient access schemes (PAS) in some markets) and the growing prevalence of...
-
27 February 2015 Cecilia Chui
Economically, the Middle East (ME) is well positioned to be the one of next growth engine of global pharmaceutical sales: several countries in...
-
20 February 2015 Cameron Lockwood
The fifty shades of grey of international reference pricing (IRP): it's a connection probably lost on the majority of those flocking to see...
-
17 February 2015 Angelica Kershaw
An improvement in relations offers the potential to open a new era in the Cuban pharma industry.
-
09 February 2015 Marinoni, Gaelle
Last year, when I shared some of our research findings on global pharmaceutical tiered pricing strategies, I highlighted the acute need for further...
-
05 February 2015 Mark Hollis
In the historic surroundings of the UK Houses of Parliament a group of leading vaccine experts and representatives of the pharmaceutical industry...
-
02 February 2015 Tania Rodrigues
The SiNATS reform represents a significant structural reform to the way health technologies will be evaluated in Portugal.
-
30 January 2015 Choukri Genane
With a target population for Sovaldi representing 70,000 to 80,000 patients in France, the potential cost for the health insurance system is...
-
27 January 2015 Gustav Ando
IHS Life Science team provides a look atthe top drivers for the industry in 2015
-
21 January 2015 Tania Rodrigues
The main aim of this collaborative IPT model is to assist with pharmaceutical pricing and reimbursement (P&R) decisions. Published on the Spanish...
-
15 January 2015 Federica Benassi
On January 1, 2015, the European Medicines Agency (EMA) started to proactively publish clinical data concerning applications for centralised...
-
12 January 2015 Brendan Melck
Greek pharmaceutical companies have had a tough year in 2014. The year started with the implementation of a new law on pharmaceutical pricing...
-
06 January 2015 Margaret Labban
US President Barack Obama issued an executive order and national strategy to combat antibiotic resistance in September 2014, almost exactly a...
-
02 January 2015 Gaelle Marinoni
Tiered drug pricing-in which pharmaceutical companies charge different prices across markets and market segments-is poised for expansion into...
-
29 December 2014 Kavita Rainova
In early November a bill was put in front of the British parliament, for second reading, proposing that new licences should be sought by the...
-
19 December 2014 Sophie Cairns
Last month, media reports surfaced over a missive that China's central pricing authority had issued to provincial pricing authorities during...
-
11 December 2014 Brendan Melck
An increasing number of new EU member states in central and south-eastern Europe are introducing new legislation to allow restrictions and bans...
-
09 December 2014 Margaret Labban
The highly anticipated trial results have reaffirmed the "LDL hypothesis" and offer a particularly positive outlook for present and future LDL...
-
03 December 2014 Milena Izmirlieva
For pharma manufacturers early access to innovation should generally translate into early patient access and earlier revenues than if a company...
-
01 December 2014 Federica Benassi
With the recent publication of the revised overarching guideline on biosimilar medicines, the European Medicines Agency (EMA) has formally introduced...
-
26 November 2014 Kavita Rainova
The recent deal termination has refocused attention on the overall political, social and economic climate in Russia, as well as specific pharmaceutical...
-
24 November 2014 Federica Benassi
I recently attended the conference HTA 2.0 Europe – Teaming Up for Value organised by EUnetHTA in Rome. here are some thoughts and take-aways...
-
21 November 2014 Praful Mehta
Using a risk ratings framework to help pharmaceutical companies better navigate and understand the changing market access landscape by quantifying...
-
19 November 2014 Cameron Lockwood
A closer look at orphan drugs, specialty drugs and rising costs in US hospitals
-
17 November 2014 Milena Izmirlieva
At the ISPOR 17th Annual European Congress earlier this week, pricing and reimbursement challenges in Central and Eastern European (CEE) countries...
-
12 November 2014 Mark Hollis
I'm at the ISPOR Europe 2014 (#isporamst2014) meeting, and an issue that keeps cropping up is vaccine pricing. This is also something that I...
-
11 November 2014 Brendan Melck
AMNOG - and the system of early benefit assessment of new innovative drugs which it introduced - remains the most widely-discussed aspect of...
-
10 November 2014 Gustav Ando
The 17th European Congress of ISPOR kicked off in a combative fashion this morning with a plenary session devoted to how to create sustainable...
-
06 November 2014 Gustav Ando
The IHS Life Sciences team is pleased to announce that we will have a strong presence at the ISPOR 17th European Congress in Amsterdam, 8-12...
-
04 November 2014 Milena Izmirlieva
In a comparatively unexpected move, Bulgaria's caretaker government has decided to introduce significant changes in the country's international...
-
27 October 2014 Margaret Labban
Canada's unprecedented "18 at 18%" national generic drug pricing agreement is set to save the healthcare system billions. On 1 April ...
-
23 October 2014 Milena Izmirlieva
This month marks ten years since our same day analysis service was the first to report on the world's first biosimilar approval in Australia....
-
20 October 2014 Federica Benassi
While an increasing number of new HCV treatments gain approval for marketing authorisation in Europe, EU member states are looking at ways to...
-
16 October 2014 Mark Hollis
Earlier this week, I appeared in CNBC to discuss the growing challenges around treating and containing Ebola. The World Health Organization...
-
07 October 2014 Gustav Ando
As we discussed in a blog earlier this year, it was clear early on this year that 2014 will be remembered as the year in which M&A activity returned...
-
26 September 2014 Cameron Lockwood
Sometimes standing still is the best way to move forward. Just ask the UK's National Institute for Health and Care Excellence (NICE), which this...
-
22 September 2014 Kavita Rainova
In the last few days, various government officials in Russia have been issuing statements saying that the import of pharmaceuticals will not...
-
04 September 2014 Sophie Cairns
When entering China, test your drugs as the Chinese do. That may not be as catchy as the saying about Romans, but it's a rule that every company...
-
21 August 2014 Marinoni, Gaelle
Tiered pricing is a commercial strategy that consists of charging different prices to different markets or market segments. In pharma, tiered...
-
14 August 2014 Gustav Ando
As the 2014 West Africa Ebola virus outbreak claims its thousandth victim, many questions are being asked over how the disease can be contained...
-
01 August 2014 Angelica Kershaw
From a government perspective, the potential benefits of biosimilars are pretty clear: they offer great potential to improve healthcare access...
-
31 July 2014 Tericke Blanchard
The development of short-term therapies that can cure life-threatening diseases, versus chronic treatments that manage the condition, are driving...
-
28 July 2014 Kavita Rainova
Over the past few weeks reports have been surfacing in the Ukrainian media over calls for the resignation of Ukraine's current Health Minister...
-
23 July 2014 Margaret Labban
The world's first Programmed cell death 1 (PD-1) inhibitor was approved in Japan this month for the treatment of advanced melanoma. This novel...
-
21 July 2014 Brendan Melck
Greece's new health minister, Makis Voridis, inherits the same overriding issue in the area of pharmaceutical policy as his predecessor - ......
-
14 July 2014 Kavita Rainova
Early this month it was reported that the amendments to Russia's drug circulation law, Federal law FZ:61, were finally passed to the country's...
-
11 July 2014 Mark Hollis
For some, any hope of a change in pharmaceutical and healthcare policy from India's much extolled new government were dashed the moment the new...
-
10 July 2014 Milena Izmirlieva
I had the pleasure of attending the European Generic Medicines Association (EGA) annual meeting a few days ago and was struck by how little has...
-
07 July 2014 Federica Benassi
Is Avastin as safe and effective as Lucentis in an ophthalmology setting? In recent years, many countries have evaluated potential risks posed...
-
23 June 2014 Tericke Blanchard
The role of big data in healthcare decision making was the central theme at ISPOR's annual meeting in Montreal earlier this month. The greater...
-
20 June 2014 Milena Izmirlieva
As Indian generics producer Dr. Reddy's announced yesterday that they want to boost their involvement in proprietary drugs and biosimilar drugs...
-
16 June 2014 Cameron Lockwood
If you build it, they will come," a voice once whispered to Kevin Costner in Field of Dreams. (Technically that's a misquote, but since ...
-
13 June 2014 Marinoni, Gaelle
The European Medicines Agency (EMA) recently launched an adaptive licensing pilot project, which was hailed by the Agency as an initiative "to...
-
04 June 2014 Margaret Labban
Negative recommendations don't always preclude market access in Canada I've been covering The Canadian Agency for Drugs and Technologies in ......
-
03 June 2014 IHS Markit Life Sciences Expert
From fraud protection to online advertising, "big data" plays a large role behind the scenes of all of our day-to-day lives. References to ......
-
30 May 2014 Gustav Ando
The IHS Life Sciences team is pleased to announce that we will again have a strong presence at the ISPOR 19th Annual International Meeting in...
-
21 May 2014 Maria McGee
Having covered drug P&R developments in the Nordic markets here at IHS and with my participation in this recent study on flexible pricing, I...
-
09 May 2014 Gustav Ando
There has been a wildfire of criticism from many sectors over Pfizer's proposed record bid to acquire AstraZeneca over the last couple of weeks....
-
28 April 2014 Kavita Rainova
The United Kingdom's National Institute of Care Excellence (NICE) has recently issued its document on Value based assessment (VBA) for consultation....
-
22 April 2014 Gustav Ando
Easter bunnies hunting for the pipeline eggs The Easter weekend of 2014 will be remembered in the pharmaceutical industry as a moment where several...
1
2